Target Price | $28.00 |
Price | $4.41 |
Potential |
534.92%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Olema Pharmaceuticals Inc 2026 .
The average Olema Pharmaceuticals Inc target price is $28.00.
This is
534.92%
register free of charge
$30.00
580.27%
register free of charge
$20.00
353.51%
register free of charge
|
|
A rating was issued by 8 analysts: 8 Analysts recommend Olema Pharmaceuticals Inc to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Olema Pharmaceuticals Inc stock has an average upside potential 2026 of
534.92%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.14 | -2.35 |
18.32% | 9.81% | |
P/E | negative |
4 Analysts have issued a Olema Pharmaceuticals Inc forecast for earnings per share. The average Olema Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Olema Pharmaceuticals Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 12 2024 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 11 2024 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 13 2024 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 24 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 12 2024 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 11 2024 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 13 2024 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 24 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.